New Stock News | Highglow Pharmaceuticals Submits Application to Hong Kong Stock Exchange Again

According to the Zhixian Finance APP, it was disclosed by the Hong Kong Stock Exchange on June 8 that Hangzhou Gaoguang Pharmaceutical Co., Ltd. (referred to as Gaoguang Pharmaceutical) has submitted an application to the Hong Kong Stock Exchange Main Board, with China International Capital Corporation and CMB International as its joint sponsors. The company had previously submitted an application for listing to the Hong Kong Stock Exchange on December 4, 2025. The prospectus shows that Gaoguang Pharmaceutical is a clinical-stage biotechnology company established in 2017, focusing on the discovery, development, and commercialization of therapies for autoimmune/inflammatory diseases. As of now, the company has developed seven small molecule candidate drugs, mainly used for the treatment of autoimmune diseases and neurodegenerative diseases, including four candidate drugs in clinical stages and three selected candidate drugs in preclinical stages.